After Denali Therapeutics announced interim results from a Phase 1b study of its eIF2B agonist, DNL343, in participants with amyotrophic lateral sclerosis, or ALS, Cantor Fitzgerald analyst Charles Duncan said he views the data as "positive" as they indicate ‘343 has pharmacokinetics that support daily oral dosing and pharmacodynamics that "may bode well for clinical efficacy." The analyst, who was also "impressed" with the safety findings, has an Overweight rating and $85 price target on Denali shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics initiated with an Outperform at Cowen
- Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
- Denali Therapeutics announces DNL343 interim Phase 1b data in ALS
- Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
- Denali Therapeutics Announces Proposed Offering of Common Stock